FLIR Introduces M300 Series Marine Cameras
FLIR Systems (NASDAQ: FLIR) today announced the FLIR M300 Series, a new generation of maritime thermal cameras delivering advanced awareness-enhancing technologies, safer navigation, and seamless integration with onboard boat systems. FLIR M300 Series cameras are designed for the most demanding professional mariners and first responders who operate in the harshest marine environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190923005214/en/
FLIR M300 Series thermal imaging cameras for professional mariners and first responders provide safer navigation and increased situational awareness (Photo: Business Wire)
The successor to FLIR’s industry-leading M-Series of maritime cameras, the next generation M300 Series consists of five models featuring rugged and robust new pan and tilt housings – four models with the FLIR Boson™ resolution thermal camera cores, plus a visible-only, high-definition (HD) model. The series is highlighted by two dual sensor models, the M364C and M364C LR, which offer mariners greater awareness via FLIR’s patented Color Thermal Vision™ (CTV) technology. This proprietary multispectral imaging technology for the FLIR M300 Series and FLIR’s Raymarine Axiom® line of navigation displays blends thermal and high-definition visible color video for enhanced identification of buoys, vessels, and other targets at night.
The M300 Series integrates with the latest-generation marine navigation displays, including FLIR’s award-winning Raymarine Axiom family of multifunction displays.
“Our FLIR M300 Series cameras employ advanced sensing and imaging technologies so first responders, commercial mariners, and recreational boaters can navigate safer in limited visibility,” said Travis Merrill, President of the Commercial Business Unit at FLIR. “These professional-grade marine cameras offer industry-leading performance and deep integration with Raymarine Axiom navigation displays to bring mariners a new level of situational awareness.”
The FLIR M300 Series range from $6,495 to $29,495 USD and are available now through FLIR’s network of maritime dealers and retailers. For more information about the FLIR M300 Series, visit http://www.flir.com/m300-series.
About FLIR Systems
Founded in 1978, FLIR Systems is a world-leading industrial technology company focused on intelligent sensing solutions for defense, industrial and commercial applications. FLIR Systems’ vision is to be "The World's Sixth Sense", creating technologies to help professionals make more informed decisions that save lives and livelihoods. For more information, please visit flir.com and follow @flir.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New subcutaneous formulation of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) shows positive Phase 1 results for the treatment of IBD in data presented at UEG Week Barcelona 201921.10.2019 01:01:00 EEST | Press release
Celltrion Healthcare today announced new data from a Phase 1 pivotal study to evaluate the pharmacokinetics (PK), efficacy and safety of CT-P13 SC compared to the CT-P13 IV formulation in people with inflammatory bowel disease (IBD). Results presented at UEG Week 2019 in Barcelona, Spain demonstrated non-inferiority of CT-P13 SC compared to CT-P13 IV in the PK primary endpoint at pre-dose level (Ctrough) at week 22, and in the secondary endpoints efficacy and safety up to week 30. In the study, 136 patients were enrolled and 131 were randomised (66 to CT-P13 SC and 65 to CT-P13 IV). After loading doses of IV 5mg/kg at weeks 0 and 2, patients were randomised at week 6 to receive either CT-P13 SC 120mg (<80kg) or 240mg (≥80kg) every 2 weeks in the CT-P13 SC arm, or CT-P13 IV 5mg/kg every 8 weeks in the CT-P13 IV arm. The Phase 1 pivotal study demonstrated that CT-P13 SC showed non-inferiority in PK to CT-P13 IV as determined by the trough concentration, pre-dose level (Ctrough) at week 2
ADX Group Announces IPO Progress, New Cyber Security Offerings21.10.2019 01:00:00 EEST | Press release
ADX Group (“ADX”), owner and operator of online business services, online entertainment, and consumer electronics, announced today that the company’s progress towards its initial public offering (IPO) has advanced. In comments the day before the company’s 11th annual Autumn Conference, ADX Founder Mr. Steven M. Renner said, “ADX has formally engaged independent auditors to commence a pre-IPO audit, and our NASDAQ IPO remains on track for early 2022.” Attending the conference on Jeju Island, South Korea, more than 700 ADX sales consultants heard updates on the company’s IPO, new ADX Cyber Security Services (including ADX Mail, ADX Cloud, ADX VPN, and WebCast.Pro secure conferencing services), YouChat secure mobile messaging services, popular AWL Cloud Hosting Services, and advances in ADX Mobile Games. “The focus of our 11th Autumn conference is ADX Cyber Security Services,” said Renner. “ADX’s advances in artificial intelligence, machine learning, deep learning, and blockchain technolo
Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia20.10.2019 02:29:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) is reimbursed in Australia for people with cystic fibrosis (CF) ages 12 years and older who are homozygous for the F508del mutation or who have one copy of the F508del mutation and another responsive residual function (RF) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. People with CF who have one copy of the F508del mutation and another responsive RF mutation in the CFTR gene will have access to a medicine for the cause of their CF for the first time. In addition, ORKAMBI® (lumacaftor/ivacaftor) is now also reimbursed for the treatment of children with CF ages 2 to 5 who have two copies of the F508del mutation in the CFTR gene. Patients over the age of 6 have already been able to access ORKAMBI® in Australia since October 2018. Following previously received positive recommendations from the Pharmaceutical Benefits Advisory Committee (PB
EURid Launches New Eligibility Criteria19.10.2019 07:30:00 EEST | Press release
The top-level internet domain .eu is the eighth largest country code extension on the internet and, as of October 2019, we have more than 3.6 million registrations spread out across Europe. Since its launch in 2006, only companies and individuals residing within the EU and EEA member states have been eligible to register the .eu domain name. However, striving to meet the needs of an ever-changing digital environment, the eligibility criteria for the registration of .eu domain name has now been extended to all EU citizens living around the world. With millions of Europeans living around the world – our hope is to provide these individuals, living far from their native lands, with a personal online platform through which they can share their stories with families and friends back home. “We are excited to be able to extend the registration criteria to EU citizens around the world. The .eu domain is now closer to your ambitions, achievements and dreams. It is the bridge connecting you to y
ams to Launch New Takeover Offer for OSRAM at EUR 41.00 Per Share With Minimum Acceptance Threshold of 55%18.10.2019 20:16:00 EEST | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION ams (SIX: AMS), a leading worldwide supplier of high performance sensor solutions, announces that it intends to launch a new all-cash takeover offer for OSRAM Licht AG ("OSRAM") for 100% of the share capital of OSRAM at a price of EUR 41.00 per share ("Offer"). The Offer which represents a premium of 42% to the undisturbed OSRAM share price of EUR 28.92 as of 2 July 2019 will be launched by ams Offer GmbH, a newly incorporated, wholly owned subsidiary of ams. ams is the largest shareholder in OSRAM with a direct shareholding of 19.99% which ams will not exceed outside of the Offer. As a result of ams' shareholder position, ams has lowered the minimum acceptance threshold to 55%. Winning way forward for ams and OSRAM The combination of ams and OSRAM allows ams to create a global leader in sensor solutio
Resecurity Appoints Selene Giupponi Managing Director of Resecurity Europe18.10.2019 18:38:00 EEST | Press release
Resecurity, a cybersecurity company that delivers in-depth analysis layered on top of the most comprehensive, exclusive sets of data from the Deep and Dark Web, announces that Selene Giupponi has joined as Managing Director and will be based in Italy. A digital forensics expert, Selene adds significant value to Resecurity’s operations in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191018005415/en/ Resecurity Appoints Selene Giupponi Managing Director of Resecurity Europe (Photo: Business Wire) Selene has extensive expertise in digital forensics and is often called as an expert witness regarding digital and mobile forensics on domestic and international cases, investigations and court trials. She is a specialized IT trainer in Italy and teaches digital, mobile, cloud and mainframe forensics, cybercrime and information security at various Italian universities. “Selene brings a depth of experience to our team and we
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom